InnoCare Pharma Initiates Phase Ib Study Combining ICP-189 with Furmonertinib for NSCLC
InnoCare Pharma (HKG: 9969, SHA: 688428), a biopharmaceutical company , has announced that the first...
Company
Novatim Immune Therapeutics’ KQ-2003 Gains Tacit Approval for POEMS Syndrome Clinical Trial in China
Novatim Immune Therapeutics (Zhejiang) Co., Ltd, a China-based specialist in cancer immunotherapy, has received tacit...
Harbour BioMed Reports Triple-Digit Revenue Growth and First-Ever Net Profit in 2023 Financial Results
Harbour BioMed (HKG: 2142), a biopharmaceutical company with a global presence in Suzhou, China, Cambridge...
Hepalink’s Enoxaparin Sodium Injection Receives Marketing Approval in New Zealand
Shenzhen Hepalink Pharmaceutical Group Co., Ltd (SHE: 002399), a prominent pharmaceutical company based in China,...
IASO Biotherapeutics Gets NMPA Go-Ahead for BCMA-Targeted CAR-T Therapy Clinical Trial
IASO Biotherapeutics, a China-based biopharmaceutical company, has announced that it has received approval from the...
WuXi AppTec Denies US Allegations of Unauthorized Intellectual Property Transfer
WuXi AppTec (SHA: 603259, HKG: 2359), a leading Contract Research, Development, and Manufacturing Organization (CRDMO)...
FDA Reviews Eisai’s Leqembi for Expanded Use as Monthly Alzheimer’s Therapy
The US Food and Drug Administration (FDA) has given the green light to review an...
WuXi AppTec Denies Unauthorized IP Transfer Allegations Amidst Strong Financial Performance
WuXi AppTec (SHA: 603259, HKG: 2359), a China-based Contract Research, Development, and Manufacturing Organization (CRDMO)...
Genor Biopharma’s Lerociclib Accepted for Review by China’s NMPA for Breast Cancer Treatment
China’s Genor Biopharma Co., Ltd (HKG: 6998) has announced that the market filing for its...
BeiGene and GenFleet Join Forces for DLBCL Trial Combining Brukinsa and GFH009
BeiGene Ltd (NASDAQ: BGNE; HKG: 6160; SHA: 688235), a China-based biotechnology company, has entered into...
RemeGen Reports 40% Revenue Growth in 2023, but Net Losses Widen Amid Pipeline Investments
RemeGen Co., Ltd (HKG: 9995; SHA: 688331), a China-based biotech firm, has unveiled its 2023...
Takeda Gains MHLW Approval for Adzynma, Targeting Rare Blood Disorder cTTP
Takeda Pharmaceutical Company (TYO: 4502) has secured regulatory approval from Japan’s Ministry of Health, Labour...
Everest Medicines Reports 884% Revenue Surge Amid Rising Losses and Strategic Shifts
Everest Medicines (HKG: 1952), a China-based biotech company, has released its 2023 annual financial results...
AstraZeneca’s Soriot Discusses US BioSecure Act’s Impact Amid China Expansion Plans
Pascal Soriot, CEO of AstraZeneca (NASDAQ: AZN), addressed the potential implications of the US BioSecure...
Shanghai Medicilon Forms Strategic Partnerships with Binhui Biopharmaceutical and Innoforce Pharmaceuticals
Shanghai Medicilon Biomedical Co., Ltd (SHA: 688202), a prominent Chinese biotech firm, has entered into...
HutchMed’s Orpathys Files for Expanded Indication in NSCLC Treatment in China
HutchMed (China) Ltd (NASDAQ: HCM; HKG: 0013) has announced that the National Medical Products Administration...
Astellas Pharma’s Padcev Combo Therapy Accepted for Review in China for Urothelial Carcinoma
Astellas Pharma Inc. (TYO: 4503), a leading Japanese pharmaceutical company, has announced that China’s Center...
AstraZeneca’s Tralokinumab Trial Data Spurs Development of Brainomix’s e-Lung Software
AstraZeneca (AZ; NASDAQ: AZN) has reported data from a Phase II trial for its idiopathic...
BeiGene Terminates Partnership with Shoreline Therapeutics for NK Cell Therapies
A close examination of BeiGene’s (NASDAQ: BGNE; HKG: 6160; SHA: 688235) recent annual report has...
Luye Pharma Group Posts 2.7% YOY Revenue Growth in 2023 with Strong Market Performance
Luye Pharma Group (HKG: 2186), a leading pharmaceutical company based in China, has announced its...